

## **Arbutus to Present at Jefferies Virtual Healthcare Conference**

May 27, 2020

WARMINSTER, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier, Arbutus' President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 PM ET.

A live webcast of the presentation can be accessed through the Investors section of Arbutus' website at <a href="www.arbutusbio.com">www.arbutusbio.com</a> or directly at <a href="www.arbutusbio.com">Live</a> <a href="www.arbutusbio.com">Webcast</a>. An archived replay of the webcast will be available on the Company's website after the conference.

## **About Arbutus**

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. For more information, visit <a href="https://www.arbutusbio.com">www.arbutusbio.com</a>.

## **Contact Information**

**Investors and Media** 

William H. Collier President and CEO Phone: 604-419-3200 Email: ir@arbutusbio.com

Pam Murphy

Investor Relations Consultant Phone: 604-419-3200 Email: <u>ir@arbutusbio.com</u>



Source: Arbutus Biopharma Corporation